China-based CanSino Biologics (HKG: 6185) has received market approval from the Badan Pengawas Obat dan Makanan (BPOM) of Indonesia for its ACYW135 Meningococcal Conjugate Vaccine (CRM197), commercially known as Menhycia.
Menhycia: Protection for Infants and Young Children
Menhycia is indicated for infants and young children aged between 3 months to 3 years (47 months). The vaccine works by stimulating the body to produce immunity against ACYW135 Neisseria meningitidis, which is responsible for causing epidemic meningitis. This approval marks a significant step in broadening the accessibility of this critical vaccine to younger demographics in Indonesia.
Safety and Immunogenicity Assessments
The product is currently undergoing assessments for safety and immunogenicity in the population aged 18 to 55 in Indonesia. Previous trials conducted in China have already demonstrated Menhycia’s good safety profile and immunogenicity, laying a solid foundation for its potential use in an expanded age range.-Fineline Info & Tech
